News

Video

What to Expect With a High Risk of Head and Neck Cancer Recurrence

Author(s):

Patients who have a higher risk of head and neck cancer recurrence can expect more — and sooner — monitoring of their disease.

A mouthwash-based test could lend insight into which patients with head and neck cancer have a higher risk of experiencing disease recurrence, according to research published in JAMA Otolaryngology — Head & Neck Surgery.

The study included 160 patients with oral or oropharyngeal tumors who used the oral rinse for up to 18 months after their first cancer treatment. The mouthwash tested for CD44 — a protein associated with cancer — and total protein levels. Findings showed that patients with higher levels of CD44 or total protein had a higher risk of disease recurrence than those with lower levels.

In a recent interview, study author Dr. Elizabeth J. Franzmann acknowledged that patients being told that they have an increased risk for recurrence could make patients feel stress and anxiety. Franzmann, who is a professor of otolaryngology and director of Head and Neck Research at the University of Miami Miller School of Medicine in Florida, discussed what patients can expect after learning that they have an increased risk of head and neck cancer recurrence.

Transcript

So there are things that can be done. For example, we may order a PET, CT scan or other imaging earlier, rather than later.

We might take them back for what we call a panendoscopy (thin, tube-like instrument to examine the nose and throat) and biopsy, which is a look [at the anatomy of cancer]. Especially for the oropharyngeal cancers, those can be hard to see in the office because of the gag reflex …and almost everybody has a gag reflex, and that's a normal thing, but it does make it hard to get a really good exam in the office. So we can take them back under general anesthesia and get a look with our special equipment that will allow us to get into the nooks and crannies of the oropharynx to be able to look for disease.

But you wouldn't want to put a person under general anesthesia unless you had a good reason to do that.

For more news on cancer updates, research and education, don’t forget to subscribe to CURE®’s newsletters here.

Related Videos
.Dr. Catherine Wu, chief of the Division of Stem Cell Transplantation and Cellular Therapies at Dana-Farber Cancer Institute, and institute member at the Broad Institute of MIT and Harvard, in Boston
Image of Doctor with blonde hair.
Dr. Katy Beckermann discusses how a Fotivda and Opdivo combination for renal cell carcinoma compared with Fotivda alone based on patient feedback.
Dr. Petros Grivas discusses what precautions should be considered when treating patients with advanced urothelial carcinoma who have diabetes.
Dr. Debu Tripathy discussed the importance of understanding the distinctions between HER2-low and HER2-ultralow breast cancer.
Primary urothelial cancer has variable histologies, making its treatment complex, leading to varied outcomes with high rates of recurrence in patients.
Dr. Neeraj Agarwal is a medical oncologist, a professor of medicine and the Presidential Endowed Chair of Cancer Research at the Huntsman Cancer Institute, University of Utah, as well as director of the Genitourinary Oncology Program and the Center of Investigational Therapeutics at the Huntsman Cancer Institute in Salt Lake City.
Image of Dr. Goy.
Image of bald man.
Dr. Tycel Phillips is an Associate Professor in the Division of Lymphoma, Department of Hematology and Hematopoietic Cell Transplantation, at City of Hope in Duarte, California.
Related Content